Laparoscopic Hysterectomy Clinical Trial
— ZIMSOfficial title:
Zip-Stitch® in Minimally-Invasive Surgery (ZIMS) - Safety & Efficacy in Hysterectomy
Verified date | March 2024 |
Source | ZSX Medical LLC |
Contact | Samantha Sam, BS |
Phone | 8566492579 |
ssam[@]zsxmedical.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to evaluate the safety and efficacy of the Zip-stitch® Vaginal Cuff Closure System. This will be primarily done by measuring the frequency of implant passing following system use. Also assessed will be relevant safety and efficacy endpoints as compared to a two-to-one reference group.
Status | Recruiting |
Enrollment | 59 |
Est. completion date | September 1, 2025 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Provision of signed and dated Informed Consent Form 2. Stated willingness to comply with all study procedures, including participation in follow-up visits and telephonic follow-up 3. Female 18 years and older 5. Indicated for Laparoscopic Hysterectomy (includes Total Laparoscopic Hysterectomy, Laparoscopic Assisted Vaginal Hysterectomy, or robotic assisted vaginal hysterectomy) Exclusion Criteria: 1. History of Human Immunodeficiency Virus (HIV) 2. History of Hepatitis C 3. History of diabetes that, in the opinion of the investigator, may delay healing 4. Current use of systemic corticosteroids 5. Active infection of genitals, vagina, cervix, uterus or urinary tract 6. Active bacteremia, sepsis or other active systemic infection 7. Presence of Sexually Transmitted Infection (STI) 8. Evidence of pelvic inflammatory disease (PID) 9. Known clotting defects or bleeding disorders 10. Hemoglobin < 8 g/dL 11. Metastatic disease 12. On anticoagulant therapy 13. Participation in another interventional trial 14. Pregnancy 15. Abnormal Papanicolaou test (PAP) results that have not been fully evaluated, or in the opinion of the investigator may indicate abnormal vaginal cuff healing 16. Co-morbidities that, in the opinion of the investigator, may indicate risk of abnormal vaginal cuff healing 17. Intra-operative: Bowel injury during laparoscopic hysterectomy procedure prior to attempted cuff closure 18. Intra-operative: Bladder injury during laparoscopic hysterectomy procedure prior to attempted cuff closure 19. Intra-operative: Cases in which surgeon cannot identify adequate tissue along the cuff to apply suture laparoscopically 20. Intra-operative: Cases requiring conversion to laparotomy prior to study intervention |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University | Chicago | Illinois |
United States | Mon Health Medical Center | Morgantown | West Virginia |
United States | Tidewater Clinical Research | Virginia Beach | Virginia |
United States | Unified Women's Clinical Research | Winston-Salem | North Carolina |
United States | Lankenau Hospital | Wynnewood | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
ZSX Medical LLC | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety: The primary safety endpoint in this study is frequency of vaginal cuff dehiscence. | Frequency of vaginal cuff dehiscence | This will be evaluated through six-weeks post-operative. | |
Primary | Efficacy: The primary efficacy endpoint for this study is frequency of implant passing following cuff closure. | Frequency of implant passing | This will be evaluated through six weeks post operative. | |
Secondary | Number of Participants With Successful Vaginal Cuff Closure | Binary, visual surgeon cuff closure evaluation. | Performed at one week, six weeks, and six months after surgery | |
Secondary | Number of Participants With Vaginal Cuff Healing | Binary, visual surgeon cuff healing evaluation. | Performed at six weeks, and six months after surgery | |
Secondary | Comparison of Number of Participants With Implant Passing - Test to Reference | Percentage of subjects experiencing implant passing will be compared between test and reference groups. | Evaluated at six weeks and six months post-operative | |
Secondary | Percentage of Participants With Implant Passing Events Determined to Impact Patient Safety | Each reported implant passing event will be evaluated for association with adverse events. Compared as a percentage of patients in the test vs. reference groups. | Evaluated through six-month follow-up | |
Secondary | Comparison of Incidence of Adverse Events - Test to Reference | Adverse events and serious adverse events will be tabulated for both the test and reference groups. | Evaluated through six-month follow-up | |
Secondary | Number of Participants With Non-increase in Dyspareunia at Follow-up | Non-increase in reported individual subject dyspareunia from baseline to six month follow-up will be compared (test versus reference group) using the relevant sexual discomfort module of the Female Sexual Function Index (FSFI). The FSFI is a validated metric of female sexual function, where lower scores indicate poor sexual function. Non-increase in sexual discomfort will be compared between test and control groups. | Evaluated through six-month follow-up | |
Secondary | Number of Participants With Non-increase in Pain at Follow-up | Non-increase in reported individual subject pain from baseline to six-month follow-up will be compared (test versus reference group) using an 11-point Numerical Rating Scale, where 0 indicates no pain, and 10 indicates maximum possible pain. | Evaluated through six-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06050161 -
Evaluating Artisential Laparoscopic Instruments in Gynecologic Surgery
|
N/A | |
Terminated |
NCT04081727 -
Zip-Stitchâ„¢ for Vaginal Cuff Closure in Laparoscopic Hysterectomy - Safety & Efficacy Study
|
N/A | |
Recruiting |
NCT05645809 -
Clinical Trial to Evaluate the Safety and Efficacy of MONOFIX® PGCL Suture in Laparoscopic Surgery
|
N/A | |
Completed |
NCT04239547 -
Effects of Recruitment Maneuver During Intraoperative Period
|
N/A | |
Completed |
NCT03144414 -
Laparoscopic Assisted Doderlin Vaginal Hysterectomy
|
N/A | |
Completed |
NCT03126162 -
Postoperative Bladder Testing After Total Laparoscopic Hysterectomy
|
N/A | |
Completed |
NCT02908841 -
Surgicel Snow in Gynecological Surgery
|
N/A | |
Completed |
NCT04972682 -
[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer
|
N/A | |
Completed |
NCT02065453 -
Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy
|
N/A | |
Recruiting |
NCT05826119 -
Intravenous Administration of Magnesium Sulfate in Laparoscopic Hysterectomy Cases
|
N/A | |
Completed |
NCT04366375 -
Pentraxin-3 in Hysterectomy Patients
|
||
Completed |
NCT03418402 -
Post Operative Pain After Laparoscopic Hysterectomy Using Airseal® Versus Standard Insufflation System
|
N/A | |
Completed |
NCT05690087 -
Lidocaine Infusion on Optic Nerve Sheath Diameter in Laparoscopic Hysterectomy in Trendelenburg Position
|
N/A | |
Completed |
NCT03350334 -
Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy
|
N/A | |
Terminated |
NCT04725981 -
Vaginal Stump Infection After Laparoscopic Hysterectomy
|
N/A | |
Completed |
NCT01344499 -
Clearance Rate of Peritoneal Fluid After Full Conditioning Pneumoperitoneum
|
N/A | |
Completed |
NCT01578759 -
Effects of Salpingectomy During Laparoscopic Hysterectomy on Ovarian Function
|
N/A |